Logo image of ANIK

ANIKA THERAPEUTICS INC (ANIK) Stock Fundamental Analysis

NASDAQ:ANIK - Nasdaq - US0352551081 - Common Stock - Currency: USD

11.15  -0.11 (-0.98%)

After market: 11.15 0 (0%)

Fundamental Rating

4

Overall ANIK gets a fundamental rating of 4 out of 10. We evaluated ANIK against 560 industry peers in the Biotechnology industry. While ANIK has a great health rating, there are worries on its profitability. While showing a medium growth rate, ANIK is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ANIK had negative earnings in the past year.
In the past year ANIK had a positive cash flow from operations.
In the past 5 years ANIK reported 4 times negative net income.
Of the past 5 years ANIK 4 years had a positive operating cash flow.
ANIK Yearly Net Income VS EBIT VS OCF VS FCFANIK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

The Return On Assets of ANIK (-29.77%) is better than 67.32% of its industry peers.
ANIK has a Return On Equity of -38.24%. This is in the better half of the industry: ANIK outperforms 71.79% of its industry peers.
Industry RankSector Rank
ROA -29.77%
ROE -38.24%
ROIC N/A
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
ANIK Yearly ROA, ROE, ROICANIK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

The Gross Margin of ANIK (60.61%) is better than 78.75% of its industry peers.
In the last couple of years the Gross Margin of ANIK has declined.
The Profit Margin and Operating Margin are not available for ANIK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
ANIK Yearly Profit, Operating, Gross MarginsANIK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

ANIK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ANIK has been reduced compared to 1 year ago.
Compared to 5 years ago, ANIK has more shares outstanding
There is no outstanding debt for ANIK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANIK Yearly Shares OutstandingANIK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M
ANIK Yearly Total Debt VS Total AssetsANIK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ANIK has an Altman-Z score of 3.91. This indicates that ANIK is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.91, ANIK is doing good in the industry, outperforming 77.32% of the companies in the same industry.
There is no outstanding debt for ANIK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.91
ROIC/WACCN/A
WACC9.47%
ANIK Yearly LT Debt VS Equity VS FCFANIK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M

2.3 Liquidity

ANIK has a Current Ratio of 5.73. This indicates that ANIK is financially healthy and has no problem in meeting its short term obligations.
ANIK has a Current ratio (5.73) which is in line with its industry peers.
ANIK has a Quick Ratio of 4.53. This indicates that ANIK is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ANIK (4.53) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.73
Quick Ratio 4.53
ANIK Yearly Current Assets VS Current LiabilitesANIK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.00% over the past year.
The Revenue for ANIK has decreased by -18.80% in the past year. This is quite bad
The Revenue has been growing slightly by 0.91% on average over the past years.
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.68%
Revenue 1Y (TTM)-18.8%
Revenue growth 3Y-6.73%
Revenue growth 5Y0.91%
Sales Q2Q%-35.42%

3.2 Future

Based on estimates for the next years, ANIK will show a very strong growth in Earnings Per Share. The EPS will grow by 28.24% on average per year.
The Revenue is expected to grow by 11.88% on average over the next years. This is quite good.
EPS Next Y58.61%
EPS Next 2Y40.02%
EPS Next 3Y23.03%
EPS Next 5Y28.24%
Revenue Next Year-26.79%
Revenue Next 2Y-10.38%
Revenue Next 3Y-5.57%
Revenue Next 5Y11.88%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ANIK Yearly Revenue VS EstimatesANIK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
ANIK Yearly EPS VS EstimatesANIK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ANIK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANIK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANIK Price Earnings VS Forward Price EarningsANIK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

91.43% of the companies in the same industry are more expensive than ANIK, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 85.22
ANIK Per share dataANIK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8 10

4.3 Compensation for Growth

ANIK's earnings are expected to grow with 23.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.02%
EPS Next 3Y23.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANIK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANIKA THERAPEUTICS INC

NASDAQ:ANIK (5/30/2025, 8:00:00 PM)

After market: 11.15 0 (0%)

11.15

-0.11 (-0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-06 2025-08-06/amc
Inst Owners87.43%
Inst Owner Change0.95%
Ins Owners2.88%
Ins Owner Change6.62%
Market Cap159.89M
Analysts86.67
Price Target23.46 (110.4%)
Short Float %2.92%
Short Ratio5.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-265.53%
Min EPS beat(2)-398.5%
Max EPS beat(2)-132.56%
EPS beat(4)0
Avg EPS beat(4)-546.51%
Min EPS beat(4)-1533.99%
Max EPS beat(4)-121.01%
EPS beat(8)1
Avg EPS beat(8)-467.12%
EPS beat(12)3
Avg EPS beat(12)-314.56%
EPS beat(16)6
Avg EPS beat(16)-204.02%
Revenue beat(2)1
Avg Revenue beat(2)-2.57%
Min Revenue beat(2)-8.59%
Max Revenue beat(2)3.46%
Revenue beat(4)1
Avg Revenue beat(4)-4.31%
Min Revenue beat(4)-9.72%
Max Revenue beat(4)3.46%
Revenue beat(8)5
Avg Revenue beat(8)-0.08%
Revenue beat(12)8
Avg Revenue beat(12)0.82%
Revenue beat(16)12
Avg Revenue beat(16)2.74%
PT rev (1m)0%
PT rev (3m)-13.21%
EPS NQ rev (1m)-142.86%
EPS NQ rev (3m)-325%
EPS NY rev (1m)-42.37%
EPS NY rev (3m)-320%
Revenue NQ rev (1m)-3.23%
Revenue NQ rev (3m)-4.48%
Revenue NY rev (1m)-2.4%
Revenue NY rev (3m)-3.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.16
P/FCF N/A
P/OCF 29.61
P/B 1.08
P/tB 1.15
EV/EBITDA 85.22
EPS(TTM)-2.1
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)0.38
OCFY3.38%
SpS9.58
BVpS10.35
TBVpS9.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.77%
ROE -38.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.61%
FCFM N/A
ROA(3y)-20.88%
ROA(5y)-13.6%
ROE(3y)-26.93%
ROE(5y)-17.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.43%
GM growth 5Y-3.15%
F-Score6
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 122.22%
Cap/Sales 6.8%
Interest Coverage N/A
Cash Conversion 431.92%
Profit Quality N/A
Current Ratio 5.73
Quick Ratio 4.53
Altman-Z 3.91
F-Score6
WACC9.47%
ROIC/WACCN/A
Cap/Depr(3y)64.17%
Cap/Depr(5y)48.11%
Cap/Sales(3y)5.41%
Cap/Sales(5y)4.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-9.68%
EPS Next Y58.61%
EPS Next 2Y40.02%
EPS Next 3Y23.03%
EPS Next 5Y28.24%
Revenue 1Y (TTM)-18.8%
Revenue growth 3Y-6.73%
Revenue growth 5Y0.91%
Sales Q2Q%-35.42%
Revenue Next Year-26.79%
Revenue Next 2Y-10.38%
Revenue Next 3Y-5.57%
Revenue Next 5Y11.88%
EBIT growth 1Y53.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100.02%
EBIT Next 3Y35.85%
EBIT Next 5Y36.1%
FCF growth 1Y19.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y102.97%
OCF growth 3Y-13.68%
OCF growth 5Y-31.94%